Brief: US FDA Approves Avlayah To Treat Neurologic Manifestations Of Hunter Syndrome
25/03/2026 16:03
March 25 (Reuters) - US FDA: US FDA - APPROVES AVLAYAH TO TREAT NEUROLOGIC MANIFESTATIONS OF HUNTER SYNDROME Further company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers